KPTI - Karyopharm Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

KPTI is currently covered by 4 analysts with an average price target of $12.93. This is a potential upside of $8.87 (218.47%) from yesterday's end of day stock price of $4.06.

Karyopharm Therapeutics's activity chart (see below) currently has 19 price targets and 25 ratings on display. The stock rating distribution of KPTI is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 32.72% with an average time for these price targets to be met of 85.82 days.

Highest price target for KPTI is $56, Lowest price target is $3, average price target is $20.25.

Most recent stock forecast was given by BRIAN ABRAHAMS from RBC on 03-Mar-2025. First documented stock forecast 02-Jun-2015.

Currently out of the existing stock ratings of KPTI, 10 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$3

$-1.16 (-27.88%)

$3

30 days ago
(03-Mar-2025)

1/8 (12.5%)

$-8.59 (-74.12%)

38

Buy

$18

$13.84 (332.69%)

$18

30 days ago
(03-Mar-2025)

0/6 (0%)

$6.41 (55.31%)

Buy

$56

$51.84 (1246.15%)

$7

30 days ago
(03-Mar-2025)

1/2 (50%)

$44.41 (383.18%)

12

Hold

$4

$2.69 (205.34%)

$10

1 years 7 months 27 days ago
(07-Aug-2023)

6/11 (54.55%)

$2.39 (148.45%)

305

Hold

$5

$3.69 (281.68%)

$6

2 years 2 months 24 days ago
(10-Jan-2023)

3/7 (42.86%)

$2.13 (74.22%)

225

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is KPTI (Karyopharm Therapeutics) average time for price targets to be met?

On average it took 85.82 days on average for the stock forecasts to be realized with a an average price target met ratio 32.72

Which analyst has the current highest performing score on KPTI (Karyopharm Therapeutics) with a proven track record?

MICHAEL ULZ

Which analyst has the most public recommendations on KPTI (Karyopharm Therapeutics)?

Michael Ulz works at MORGAN STANLEY and has 12 price targets and 7 ratings on KPTI

Which analyst is the currently most bullish on KPTI (Karyopharm Therapeutics)?

Edward White with highest potential upside - $51.84

Which analyst is the currently most reserved on KPTI (Karyopharm Therapeutics)?

Brian Abrahams with lowest potential downside - -$1.16

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?